Corgenix gets USD 2.9m govt grant to advance development of Ebola rapid diagnostic test kit.
M2 PHARMA-June 27, 2014-Corgenix gets USD 2.9m govt grant to advance development of Ebola rapid diagnostic test kit
(C)2014 M2 COMMUNICATIONS
27 June 2014 - US diagnostic test kits developer Corgenix Medical Corporation (OTCMKTS:CONX) said Thursday it had received a three-year Phase II grant, worth USD 2.9 million (EUR 2.1m), from the National Institutes of Health (NIH) to further the development of an Ebola rapid diagnostic test kit.
Corgenix will work on the project with members of the Viral Hemorrhagic Fever Consortium (VHFC), which includes academic and industry members headed by Tulane University and partly funded by the NIH.
The award will allow the collaborators to advance the development of a point-of-care test kit for use in any clinical or field laboratory to find in minutes if a person is infected with Ebola. Current testing for the Ebola virus requires special biohazard handling and sending test samples long distances to special laboratories, which takes several days.
The award follows a prior two-year grant for the development of special proteins to be used in testing. It is also the fifth major grant or contract received by Corgenix and its VHFC partners to fight dangerous viral hemorrhagic fevers, such as Ebola, Lassa and Marburg viruses. The partners have already developed and CE-marked the ReLASV rapid test for the Lassa fever virus.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Date:||Jun 27, 2014|
|Previous Article:||Mor-NuCo develops blood test detecting 27 cancer types.|
|Next Article:||Roche enters into research collaboration with Stratos Genomics.|